Improved lipid target level attainment in patients with peripheral artery disease.
CONCLUSION: It appears that there is more awareness and improvement of previously documented undertreatment of LDL-C levels in symptomatic PAD patients. Although statin treatment is initiated in the majority of patients, our findings call for a continuously intensified LLT in symptomatic PAD patients.
PMID: 33430734 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - Category: Drugs & Pharmacology Authors: Dopheide JF, Adam L, Wiedmer S, Kaspar M, Silbernagel G, Baumgartner I, Drexel H Tags: Curr Vasc Pharmacol Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Crestor | Drugs & Pharmacology | Heart | Intermittent Claudication | Lipitor | Peripheral Vascular Disease (PVD) | Rosuvastatin | Simvastatin | Statin Therapy | Study | Zivast | Zocor